| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_594df243712f7d149bfa7cb6dc55cf0d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70514
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-66 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00 |
| filingDate |
1996-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c60fc19203cd4a32dbce053e79bc17df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3820b54c6bdf037f454d1ad49e4913f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a7baabd6799a4c6db536fb03d4b94fd |
| publicationDate |
2002-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2207760-C |
| titleOfInvention |
Anti alpha-galactosyl screening technique |
| abstract |
Compounds and libraries are labeled with a galactosyl epitope and then screened in accordance with an assay involving cells having a characteristic of interest. Conveniently, the screening may embody target cells, where the compounds are brought in contact with the cells. Each of the compounds carri es with it the information of its identity or method of synthesis. After washin g away non-specifically bound compounds, blood may be applied to the cells, whereby antibody binding to the galactosyl epitope initiates the complement cascade. Plaques are identified and the compound associated with the plaque identified. The formation of the plaque demonstrates that the compound has specific affinity for the target cell, binding of the compound to the cell does not interfere with binding of the antibody, and that the complex is capable of cytotoxic activity by means of the complement cascade. |
| priorityDate |
1995-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |